COVOVAX
COVID-19 Vaccine Covovax As Heterologous Booster Dose To Be Available on CoWIN Soon, Check Price Here
COVID-19 Vaccine Booster Dose: DGCI Approves Market Authorisation of Serum Institute's Covovax as Precautionary Jab
DCGI Approves Market Authorisation for SII’s COVID-19 Vaccine ‘Covovax’ As Heterologous Booster Dose
COVID-19: Covovax Vaccine To Get Booster Dose Approval in 10–15 Days, Says SII CEO Adar Poonawalla
COVID-19 Vaccine Update: Serum Institute of India Will Try To Launch Omicron-Specific Vaccine After Six Months, Says Adar Poonawalla
COVID-19 Vaccine: 'Covovax Will Be Used for Children; First Time Made in India Vaccine Sold in Europe', Says Adar Poonawalla
COVID-19 Vaccine Update: Govt Panel Recommends Covovax Inclusion in Vaccination Drive for 12 and Above
DCGI's EUA Nod to SII's Covovax For 12-17 Years Age Group; Adar Poonawalla Says Younger Age Groups to Follow Shortly
COVID-19 Vaccination Update: Govt Panel Recommends Permission for Phase-3 Trial of Covovax as Booster Dose in Adults
Molnupiravir, COVID-19 Antiviral Drug, Launched in India at Rs 1,399 For Mild to Moderate Infection
‘Covovax Better Booster for Covishield-Vaccinated People’, Says Virologist Dr Shahid Jameel
Corbevax, Covovax, Anti-Viral Drug Molnupiravir Approved by Drug Regulator CDSCO In Fight Against COVID-19
Google Trends